Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis

// Xiangrong Cui 1, 2, 3, * , Xuan Jing 5, * , Chunlan Long 1, 2, 3 , Jie Tian 4 , Jing Zhu 1, 2, 3 1 Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, 400014, China 2 China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, 400014, China 3 Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China 4 Cardiovascular Department (Internal Medicine), Children's Hospital of Chongqing Medical University, Chongqing, 400014, China 5 Clinical Laboratory, Shanxi Province People’s Hospital, Shanxi, 030000, China * These authors contributed equally to this work Correspondence to: Jing Zhu, email: 412232858@qq.com Keywords: lncRNA, MEG3, clinical outcome, carcinoma, meta-analysis Received: December 05, 2016      Accepted: January 11, 2017      Published: February 01, 2017 ABSTRACT Numerous studies have demonstrated that the expression level of maternally expressed gene 3 (MEG3) was lost in various cancers. Low expression of MEG3 is associated with an increased risk of metastasis and a poor prognosis in cancer patients. This meta-analysis investigated the association between MEG3 levels and distant metastasis (DM), lymph node metastasis (LNM), overall survival (OS), and recurrence-free survival (RFS) of cancer patients. A total of 536 participants from 9 articles were finally enrolled. The results showed a significant negative association between MEG3 levels and DM (OR = 2.16, 95% CI = 0.99–4.71, P = 0.05, fixed-effect), and it could also predict poor OS (HR = 0.43, 95% CI = 0.15–1.24, P = 0.006, fixed-effect) and RFS (HR = 0.52, 95% CI = 0.29–0.92, P = 0.02, fixed-effect) in cancer patients. In conclusion, this meta-analysis indicated that MEG3 might serve as a potential novel biomarker for indicating the clinical outcomes in human cancers.